DK1261602T3 - Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer - Google Patents
Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorerInfo
- Publication number
- DK1261602T3 DK1261602T3 DK01907980T DK01907980T DK1261602T3 DK 1261602 T3 DK1261602 T3 DK 1261602T3 DK 01907980 T DK01907980 T DK 01907980T DK 01907980 T DK01907980 T DK 01907980T DK 1261602 T3 DK1261602 T3 DK 1261602T3
- Authority
- DK
- Denmark
- Prior art keywords
- sub
- sup
- alkyl
- hydrogen
- optionally substituted
- Prior art date
Links
- 102000009929 raf Kinases Human genes 0.000 title abstract 2
- 108010077182 raf Kinases Proteins 0.000 title abstract 2
- NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical class NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0005357.9A GB0005357D0 (en) | 2000-03-06 | 2000-03-06 | Compounds |
| PCT/GB2001/000916 WO2001066540A1 (en) | 2000-03-06 | 2001-03-02 | Imidazol-2-carboxamide derivatives as raf kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1261602T3 true DK1261602T3 (da) | 2004-08-30 |
Family
ID=9887051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01907980T DK1261602T3 (da) | 2000-03-06 | 2001-03-02 | Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6987119B2 (da) |
| EP (1) | EP1261602B1 (da) |
| JP (1) | JP2003525937A (da) |
| AT (1) | ATE266021T1 (da) |
| AU (1) | AU2001235844A1 (da) |
| DE (1) | DE60103133T2 (da) |
| DK (1) | DK1261602T3 (da) |
| ES (1) | ES2217118T3 (da) |
| GB (1) | GB0005357D0 (da) |
| PT (1) | PT1261602E (da) |
| TR (1) | TR200401903T4 (da) |
| WO (1) | WO2001066540A1 (da) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| EP1233769B1 (en) | 1999-11-22 | 2007-12-26 | SmithKline Beecham plc | Imidazole derivatives |
| EP1263753B1 (en) * | 2000-03-06 | 2004-05-06 | SmithKline Beecham plc | Imidazol derivatives as raf kinase inhibitors |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| GB0121488D0 (en) * | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| GB0121494D0 (en) * | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| JP2005505562A (ja) * | 2001-09-05 | 2005-02-24 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Ｒａｆキナーゼ阻害剤としてのピリジルフランおよびピロール |
| US20040192689A1 (en) * | 2001-09-05 | 2004-09-30 | Dean David Kenneth | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| WO2003068228A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| AR038966A1 (es) * | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
| CA2497240A1 (en) | 2002-08-29 | 2004-03-11 | Andrew Asher Protter | Methods of promoting osteogenesis |
| DE602004007382T2 (de) | 2003-05-20 | 2008-04-17 | Bayer Pharmaceuticals Corp., West Haven | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
| NZ544920A (en) | 2003-07-23 | 2009-11-27 | Bayer Healthcare Llc | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| WO2005030091A2 (en) | 2003-09-25 | 2005-04-07 | Scios Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
| US20050282909A1 (en) * | 2003-11-14 | 2005-12-22 | Diks Sander H | Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction |
| NZ553087A (en) * | 2004-08-31 | 2010-12-24 | Astrazeneca Ab | Quinazolinone derivatives and their use as B-raf inhibitors |
| CN101010303A (zh) * | 2004-09-01 | 2007-08-01 | 阿斯利康(瑞典)有限公司 | 喹唑啉酮衍生物和它们作为b－raf抑制剂的用途 |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| EP1951234A2 (en) * | 2005-10-18 | 2008-08-06 | Janssen Pharmaceutica N.V. | Method of inhibiting flt3 kinase |
| US8697716B2 (en) * | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| KR101367646B1 (ko) | 2006-04-20 | 2014-02-27 | 얀센 파마슈티카 엔.브이. | Ｃ-ｆｍｓ 키나제의 저해제 |
| CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US8324395B2 (en) | 2007-08-23 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US8344135B2 (en) | 2007-08-29 | 2013-01-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| CN102015686B (zh) * | 2008-03-21 | 2014-07-02 | 诺华股份有限公司 | 杂环化合物及其用途 |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| EP2399921B1 (en) | 2008-12-01 | 2015-08-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| KR20140011780A (ko) | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| JP7309614B2 (ja) | 2017-05-02 | 2023-07-18 | ノバルティス アーゲー | 組み合わせ療法 |
| CN113795490A (zh) | 2019-05-13 | 2021-12-14 | 诺华股份有限公司 | N-(3-(2-(2-羟基乙氧基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-2(三氟甲基)异烟酰胺的新结晶形式作为Raf抑制剂治疗癌症 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD201677A5 (de) | 1980-07-25 | 1983-08-03 | Ciba Geigy | Verfahren zur herstellung von trisubstituierten imidazolderivaten |
| US5236917A (en) | 1989-05-04 | 1993-08-17 | Sterling Winthrop Inc. | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| US5620999A (en) | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
| US5514505A (en) | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| AU6269496A (en) | 1995-06-12 | 1997-01-09 | G.D. Searle & Co. | Combination of a cyclooxygenase-2 inhibitor and a leukotrien e b4 receptor antagonist for the treatment of infla mmations |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| CN1117082C (zh) * | 1995-10-06 | 2003-08-06 | 麦克公司 | 具有抗癌和细胞活素抑制活性的取代咪唑类化合物 |
| GB2306108A (en) * | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
| AU727939B2 (en) | 1996-04-03 | 2001-01-04 | Merck & Co., Inc. | A method of treating cancer |
| JP3418624B2 (ja) | 1996-06-10 | 2003-06-23 | メルク エンド カンパニー インコーポレーテッド | サイトカイン阻害活性を有する置換イミダゾール類 |
| EP1977749A1 (en) | 1996-10-15 | 2008-10-08 | G.D. Searle LLC | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| AU8757098A (en) | 1997-06-30 | 1999-02-10 | Ortho-Mcneil Pharmaceutical, Inc. | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
| JPH11193281A (ja) | 1997-10-27 | 1999-07-21 | Takeda Chem Ind Ltd | アデノシンａ３受容体拮抗剤およびチアゾール化合物 |
| DE1049664T1 (de) * | 1997-12-22 | 2001-05-03 | Bayer Corp., Pittsburgh | Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen |
| HUP0102058A3 (en) | 1998-05-22 | 2002-05-28 | Smithkline Beecham Corp | Novel 2-alkyl substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and their use |
| EP1233769B1 (en) | 1999-11-22 | 2007-12-26 | SmithKline Beecham plc | Imidazole derivatives |
| EP1343779B1 (en) | 2000-11-20 | 2007-06-27 | Smithkline Beecham Corporation | Novel compounds |
-
2000
- 2000-03-06 GB GBGB0005357.9A patent/GB0005357D0/en not_active Ceased
-
2001
- 2001-03-02 WO PCT/GB2001/000916 patent/WO2001066540A1/en not_active Ceased
- 2001-03-02 AU AU2001235844A patent/AU2001235844A1/en not_active Abandoned
- 2001-03-02 DK DK01907980T patent/DK1261602T3/da active
- 2001-03-02 US US10/220,675 patent/US6987119B2/en not_active Expired - Fee Related
- 2001-03-02 PT PT01907980T patent/PT1261602E/pt unknown
- 2001-03-02 DE DE60103133T patent/DE60103133T2/de not_active Expired - Fee Related
- 2001-03-02 EP EP01907980A patent/EP1261602B1/en not_active Expired - Lifetime
- 2001-03-02 ES ES01907980T patent/ES2217118T3/es not_active Expired - Lifetime
- 2001-03-02 JP JP2001565356A patent/JP2003525937A/ja not_active Withdrawn
- 2001-03-02 AT AT01907980T patent/ATE266021T1/de not_active IP Right Cessation
- 2001-03-02 TR TR2004/01903T patent/TR200401903T4/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE266021T1 (de) | 2004-05-15 |
| ES2217118T3 (es) | 2004-11-01 |
| GB0005357D0 (en) | 2000-04-26 |
| DE60103133T2 (de) | 2004-10-14 |
| US20030134837A1 (en) | 2003-07-17 |
| AU2001235844A1 (en) | 2001-09-17 |
| EP1261602A1 (en) | 2002-12-04 |
| PT1261602E (pt) | 2004-08-31 |
| DE60103133D1 (de) | 2004-06-09 |
| US6987119B2 (en) | 2006-01-17 |
| EP1261602B1 (en) | 2004-05-06 |
| TR200401903T4 (tr) | 2004-09-21 |
| JP2003525937A (ja) | 2003-09-02 |
| WO2001066540A1 (en) | 2001-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1261602T3 (da) | Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer | |
| ATE266022T1 (de) | Imidazol derivate als raf kinase inhibitoren | |
| EP1724262A4 (en) | 1- (2H) -ISOCHINOLONDERIVAT | |
| EA200970461A1 (ru) | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| NO20023218L (no) | 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer | |
| RU2007110629A (ru) | Ингибиторы днк-пк | |
| SE0202463D0 (sv) | Novel compounds | |
| NO20082101L (no) | Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer | |
| TNSN03110A1 (en) | Azaindoles. | |
| HRP20040429B1 (hr) | Derivati sulfonamida, njihova priprema i upotrebakao lijekova | |
| EP1939175A4 (en) | SULFONAMIDE DERIVATIVITY WITH PGD2 RECEPTOR ANTAGONISTIC EFFECT | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| EA200601235A1 (ru) | Производные тиазола | |
| NO20063231L (no) | Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer | |
| HUP0400246A2 (hu) | 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra | |
| SE0400284D0 (sv) | Novel compounds | |
| DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| ATE403653T1 (de) | Pyridin-substituierte furanderivate als raf- kinase inhibitoren | |
| DK1320526T3 (da) | Farmaceutisk aktive benzsulfonamidderivater som inhibitorer af protein-junkinaser | |
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
| EA200701780A1 (ru) | Противоопухолевое средство | |
| PT1572198E (pt) | Novos compostos farmaceuticos com actividade de receptor alfa2. | |
| DK1899331T3 (da) | Homomorpholinoxazolidnoner som antibakterielle midler | |
| ATE409698T1 (de) | 1,2,4-triazolderivat, verfahren zu dessen herstellung, und dieses enthaltende pharmazeutische zusammensetzung |